08:22 AM EDT, 07/09/2024 (MT Newswires) -- UniQure ( QURE ) on Tuesday said updated interim data in clinical trials of its Huntington's drug AMT-130 showed slowing of disease progression.

Data from the treatment of 29 patients in ongoing phase 1 and 2 clinical trials of the investigational drug showed up to 80% reduction in neurodegeneration compared to a control group, the company said.

The company said it hopes to hold an initial multi-disciplinary Regenerative Medicine Advanced Therapy Designation meeting in the second half of the year with the US Food and Drug Administration to discuss potential expedited clinical development of AMT-130.

Shares of the company were up 23% in Tuesday's premarket activity.

Price: 4.6717, Change: +0.89, Percent Change: +23.59